Evidence map›Paper›PMID 39975078›Full record

ArticlebioRxiv : the preprint server for biology2025

Active DNA demethylation is upstream of rod-photoreceptor fate determination and required for retinal development.

Ismael Hernández-Núñez, Alaina Urman, Xiaodong Zhang, William Jacobs, Christy Hoffman, Sohini Rebba, Ellen G Harding, Qiang Li, Fengbiao Mao, Andi K Cani and 6 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Ismael Hernández-NúñezJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.
Alaina UrmanCenter for Pharmacogenetics, Washington University School of Medicine, St. Louis, MO, USA.
Xiaodong ZhangJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.
William JacobsCenter for Pharmacogenetics, Washington University School of Medicine, St. Louis, MO, USA.
Christy HoffmanJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.
Sohini RebbaJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.
Ellen G HardingJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.
Qiang LiDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
Fengbiao MaoDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-0852-4266
Andi K CaniDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Shiming ChenJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.
Meelad M DawlatyRuth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Department of Genetics, and Department of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0003-3121-2500
Rajesh C RaoDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-5776-8366
Philip A RuzyckiJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-3520-6407
John R EdwardsCenter for Pharmacogenetics, Washington University School of Medicine, St. Louis, MO, USA.
Brian S ClarkJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-7291-2055

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
WASHINGTON UNIVERSITY CENTER VISION RESEARCHP30EY002687 · NEI · WASHINGTON UNIVERSITY · PI Philip Andrew Ruzycki · 1985 to 2026
$18.4M
VIVARIUM MODULEP30EY007003 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti · 1987 to 2026
$17.6M
Vulnerable and Resilient Cells in Retinal DegenerationR01EY012543 · NEI · WASHINGTON UNIVERSITY · PI SHIMING CHEN, Philip Raymond Williams · 2000 to 2026
$12.2M
Research Training Program in the Vision SciencesT32EY013360 · NEI · WASHINGTON UNIVERSITY · PI SHIMING CHEN, Daniel Kerschensteiner · 2000 to 2026
$5.6M
Molecular Determinants for WDR5-Driven Transcriptional Regulation at Lineage-Specifying Genes During RetinogenesisR01EY030989 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, RAJESH C. · 2020 to 2024
$2.2M
Understanding and treating CRX-linked retinopathiesR01EY032136 · NEI · WASHINGTON UNIVERSITY · PI CHEN, SHIMING · 2021 to 2025
$1.9M
Regulation of Retinal Development by RNA moleculesR01EY035381 · NEI · WASHINGTON UNIVERSITY · PI Brian S Clark · 2024 to 2026
$1.4M
Homeostasis of the Retinal EpigenomeR01EY036368 · NEI · WASHINGTON UNIVERSITY · PI Philip Andrew Ruzycki · 2024 to 2026
$1.2M
Identification of the molecular mechanisms mediating intrinsic control of retinal progenitor competenceR00EY027844 · NEI · WASHINGTON UNIVERSITY · PI CLARK, BRIAN S · 2019 to 2021
$739k
NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA046592NCI NIH HHS P30 CA091842NEI NIH HHS K08 EY026654NEI NIH HHS P30 EY002687NEI NIH HHS P30 EY007003NEI NIH HHS R00 EY027844NEI NIH HHS R01 EY012543NEI NIH HHS R01 EY030989NEI NIH HHS R01 EY032136NEI NIH HHS R01 EY035381NEI NIH HHS R01 EY036368NEI NIH HHS T32 EY013360
6 · The paper itself

Abstract

Retinal cell fate specification from multipotent retinal progenitors is governed by dynamic changes in chromatin structure and gene expression. Methylation at cytosines in DNA (5mC) is actively regulated for proper control of gene expression and chromatin architecture. Numerous genes display active DNA demethylation across retinal development; a process that requires oxidation of 5mC to 5-hydroxymethylcytosine (5hmC) and is controlled by the ten-eleven translocation methylcytosine dioxygenase (TET) enzymes. Using an allelic series of conditional TET enzyme mutants, we determine that DNA demethylation is required upstream of NRL and NR2E3 expression for the establishment of rod-photoreceptor fate. Using histological, behavioral, transcriptomic, and base-pair resolution DNA methylation analyses, we establish that inhibition of active DNA demethylation results in global changes in gene expression and methylation patterns that prevent photoreceptor precursors from adopting a rod-photoreceptor fate, instead producing a retina in which all photoreceptors specify as cones. Our results establish the TET enzymes and DNA demethylation as critical regulators of retinal development and cell fate specification, elucidating a novel mechanism required for the specification of rod-photoreceptors.

Identifiers

PMID39975078
PMCPMC11838574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.